Lv11
28 积分 2024-02-20 加入
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
2小时前
已完结
EGFR19与21号外显子突变的晚期非小细胞肺癌一线TKI治疗疗效差异的研究进展
5小时前
已关闭
Development of PI3K inhibitors: Advances in clinical trials and new strategies (Review)
1个月前
已完结
Molecular docking and dynamics based approach for the identification of kinase inhibitors targeting PI3Kα against non-small cell lung cancer: a computational study
1个月前
已完结
A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R
3个月前
已完结
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
3个月前
已完结
Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial
3个月前
已完结
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
3个月前
已完结
Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations
3个月前
已完结
Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer
3个月前
已完结
皖公网安备34019202002308
